S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.76%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.76%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.76%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)
S&P 500   5,123.41 (-1.46%)
DOW   37,983.24 (-1.24%)
QQQ   438.27 (-1.59%)
AAPL   176.55 (+0.86%)
MSFT   421.90 (-1.41%)
META   511.90 (-2.15%)
GOOGL   157.73 (-1.05%)
AMZN   186.13 (-1.54%)
TSLA   171.05 (-2.03%)
NVDA   881.86 (-2.68%)
AMD   163.28 (-4.23%)
NIO   4.11 (-7.85%)
BABA   71.29 (-4.76%)
T   16.31 (-0.67%)
F   12.61 (-3.30%)
MU   122.52 (-3.91%)
GE   154.63 (-1.76%)
CGC   7.80 (-4.29%)
DIS   114.01 (-2.68%)
AMC   2.65 (-5.36%)
PFE   25.86 (-1.82%)
PYPL   64.59 (-1.84%)
XOM   120.37 (-1.17%)

Bolt Biotherapeutics (BOLT) News Today

$1.20
-0.07 (-5.51%)
(As of 04:00 PM ET)
SourceHeadline
finanznachrichten.de logoBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
finanznachrichten.de - March 22 at 6:43 AM
globenewswire.com logoBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
globenewswire.com - March 21 at 4:05 PM
globenewswire.com logoBolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
globenewswire.com - February 27 at 7:00 AM
markets.businessinsider.com logoBuy Rating Affirmed for GlycoMimetics Amidst Phase 3 Progress and Breakthrough Therapy Designation for Uproleselan
markets.businessinsider.com - January 4 at 7:57 AM
finance.yahoo.com logoBolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
finance.yahoo.com - December 5 at 7:28 AM
markets.businessinsider.com logoPromising Clinical Trial Results and Strong Financial Outlook Propel Buy Rating for Bolt Biotherapeutics
markets.businessinsider.com - November 11 at 9:52 AM
morningstar.com logoBolt Biotherapeutics Inc Ordinary Shares BOLT
morningstar.com - November 9 at 7:45 PM
finance.yahoo.com logoBolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - November 9 at 7:45 PM
finance.yahoo.com logoBolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
finance.yahoo.com - October 23 at 12:45 PM
finance.yahoo.com logoBolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
finance.yahoo.com - October 17 at 8:07 AM
finance.yahoo.com logoBolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
finance.yahoo.com - September 28 at 7:54 AM
finance.yahoo.com logoBolt Biotherapeutics to Participate in September Investor Conferences
finance.yahoo.com - September 5 at 8:29 PM
msn.com logoDynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates
msn.com - August 3 at 8:26 PM
finance.yahoo.com logoUS0977021049.SG - Bolt Biotherapeutics Inc.
finance.yahoo.com - June 17 at 11:56 AM
markets.businessinsider.com logoBolt Biotherapeutics (BOLT) Receives a Buy from H.C. Wainwright
markets.businessinsider.com - May 26 at 7:38 AM
msn.com logoSVB Leerink Upgrades Bolt Biotherapeutics (BOLT)
msn.com - May 13 at 8:01 AM
msn.com logoHC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy Recommendation
msn.com - May 13 at 8:01 AM
markets.businessinsider.com logoJonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)
markets.businessinsider.com - May 12 at 4:20 PM
finanznachrichten.de logoBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
finanznachrichten.de - May 12 at 4:43 AM
finance.yahoo.com logoBolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
finance.yahoo.com - April 26 at 1:52 PM
finance.yahoo.com logoInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last year
finance.yahoo.com - April 11 at 8:23 AM
finanznachrichten.de logoBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
finanznachrichten.de - March 30 at 10:05 AM
finance.yahoo.com logoBolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
finance.yahoo.com - March 14 at 5:25 PM
reuters.com logoBOLT.O - | Stock Price & Latest News | Reuters
reuters.com - January 21 at 1:51 PM
finance.yahoo.com logoHere's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation
finance.yahoo.com - January 4 at 12:28 PM
finance.yahoo.com logoInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last year
finance.yahoo.com - November 2 at 4:10 PM
finance.yahoo.com logoBolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference
finance.yahoo.com - November 1 at 10:53 AM
morningstar.com logoBolt Biotherapeutics Inc Ordinary Shares
morningstar.com - September 10 at 12:35 AM
finance.yahoo.com logoBolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
finance.yahoo.com - August 31 at 11:39 AM
benzinga.com logoBolt Biotherapeutics (NASDAQ:BOLT), Earnings Estimates, EPS, and Revenue
benzinga.com - August 12 at 6:36 PM
finance.yahoo.com logoThe past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitable
finance.yahoo.com - May 26 at 8:54 AM
finance.yahoo.com logoBolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
finance.yahoo.com - March 30 at 6:36 PM
seekingalpha.com logoBolt Biotherapeutics GAAP EPS of -$0.73 misses by $0.04, revenue of $0.51M
seekingalpha.com - March 30 at 6:36 PM
finance.yahoo.com logoBolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022
finance.yahoo.com - March 8 at 7:37 PM
finance.yahoo.com logoBolt Biotherapeutics, Inc. (BOLT)
finance.yahoo.com - February 10 at 8:17 PM
marketbeat.com logoBolt Biotherapeutics (NASDAQ:BOLT) Downgraded by Zacks Investment Research
marketbeat.com - February 7 at 6:20 PM
finance.yahoo.com logoBolt Biotherapeutics to Participate in Upcoming February Conferences
finance.yahoo.com - February 2 at 9:03 AM
finance.yahoo.com logoBolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
finance.yahoo.com - January 6 at 10:13 AM
marketbeat.com logoMorgan Stanley Downgrades Bolt Biotherapeutics (NASDAQ:BOLT) to Equal Weight
marketbeat.com - January 6 at 8:17 AM
marketbeat.com logoBolt Biotherapeutics, Inc. (NASDAQ:BOLT) Given Average Recommendation of "Buy" by Analysts
marketbeat.com - January 2 at 6:21 AM
marketwatch.com logoBolt Biotherapeutics Shares Rise 12% After CFO Buys 5,000 Shares
marketwatch.com - December 11 at 11:03 PM
finance.yahoo.com logoBolt Biotherapeutics Stock Halves on Mediocre Trial Data
finance.yahoo.com - December 6 at 5:33 PM
finance.yahoo.com logoWhy Bolt Biotherapeutics Stock Crashed Today
finance.yahoo.com - December 6 at 5:33 PM
marketwatch.com logoBolt Biotherapeutics Interim Data Shows BDC-1001 Cancer Treatment Well-Tolerated
marketwatch.com - December 6 at 7:32 AM
finance.yahoo.com logoBolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
finance.yahoo.com - December 6 at 7:32 AM
finance.yahoo.com logoBolt Biotherapeutics Announces Changes to its Board of Directors
finance.yahoo.com - November 19 at 8:13 AM
finance.yahoo.com logoBolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting
finance.yahoo.com - November 12 at 8:34 AM
finance.yahoo.com logoBolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
finance.yahoo.com - November 9 at 7:44 AM
apnews.com logoBolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for ...
apnews.com - October 2 at 4:40 AM
finance.yahoo.com logoBolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)
finance.yahoo.com - October 1 at 8:36 AM
Get Bolt Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter.

Buy Alert: Get these AI trades on repeat (Ad)

With this AI Trade Finder, one of my newer students took his trading account from $1,500 to over $9,400 in just over a month

Click Here To Get My Daily List of AI Generated Trades

BOLT Media Mentions By Week

BOLT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BOLT
News Sentiment

1.89

0.61

Average
Medical
News Sentiment

BOLT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BOLT Articles
This Week

1

0

BOLT Articles
Average Week

Get Bolt Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:BOLT) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners